Core Viewpoint - The global dietary nutrition and sports nutrition market is experiencing strong demand due to aging populations and increased health awareness, with significant growth in core product segments like HMB and glucosamine. Jiyuan Group is leveraging this trend to expand its market presence [2][3]. Market Demand and Growth - The demand for dietary supplements is continuously increasing, driven by rising living standards and health consciousness, with the market size expanding year by year. The global HMB production is projected to grow from approximately 1,662.43 tons in 2023 to 3,571.69 tons by 2030, reflecting a compound annual growth rate (CAGR) of about 11.54% [3][5]. Company Performance - Jiyuan Group, as the largest global supplier of HMB, holds a 53.34% market share. The company's revenue for 2024 is expected to reach 1 billion yuan, with a year-on-year growth of over 15% anticipated for the first half of 2025. The revenue figures for 2022, 2023, and 2024 are 947 million yuan, 892 million yuan, and 1 billion yuan respectively, with net profits of 142 million yuan, 160 million yuan, and 174 million yuan [5][6]. Product Portfolio and Applications - Jiyuan Group's main products include HMB, glucosamine, and chondroitin sulfate, which cater to muscle and joint health. The increasing focus on healthy lifestyles and the growing number of athletes are driving demand for supplements that enhance performance and recovery [3][5]. Technological Innovation - The company has established a differentiated advantage through technological innovation and quality assurance. Jiyuan Group focuses on R&D and has developed proprietary technologies for HMB synthesis, ensuring high purity and compliance with international standards [7][9]. Quality and Safety Standards - Jiyuan Group emphasizes product quality and safety, adhering to strict quality management systems and obtaining various certifications, including GMP and USP. This commitment to quality has helped the company build a strong brand reputation and customer loyalty [10][11][12]. Strategic Partnerships - The company has formed long-term partnerships with renowned brands such as Abbott and Nutramax, enhancing its market position and ensuring stable demand for its products [9][10]. Future Outlook - With a dual focus on technology and quality, Jiyuan Group is poised to lead the global dietary nutrition supplement sector, contributing significantly to the health industry [13].

AI and Market Trends - AI applications are entering a rapid growth phase, supported by mature infrastructure and decreasing costs of large model calls, enhancing commercial potential[3] - China possesses significant data reserves and a broad demand scale, providing a competitive advantage for AI development[3] Market Performance - The A-share market experienced a general rise, with the Shanghai Composite Index up by 1.67% and the Shenzhen Component Index up by 2.33% during the week[15] - Mid-cap indices such as the CSI 500 and CSI 1000 outperformed large-cap indices, with increases of 3.28% and 2.38% respectively[17] Dietary Supplements Industry - The global dietary supplement market is projected to reach $223 billion by 2026, driven by population growth and increasing health awareness[5] - HMB, a key nutrient for muscle health, is expected to see global production reach 3,572 tons by 2030, indicating strong market potential[5] Investment Recommendations - Recommended stocks include Toris (拓尔思), which has a robust open-source intelligence data resource, and Songlin Technology (松霖科技), focusing on health robots[3] - Other notable mentions are Rongxin Culture (荣信文化), which is expanding into AI+ education scenarios[3] Corporate Actions - This week, two companies listed on the A-share market, with C Shanda and C Jiyuan seeing first-day gains of 356% and 274% respectively[33] - There were six new public offerings announced, with an average discount rate of 18.9% and an average return of 40.7% on recent fundraising projects[34][40]

Core Insights - The company has over 20 years of experience in the global dietary supplement industry, focusing on scientific research and clinical trials to provide innovative and customized nutritional ingredients and formulations [1] - In 2024, the company achieved a revenue of 1.002 billion yuan, representing a year-on-year growth of 12.33% [1] Industry Overview - The global dietary supplement market exceeded $187 billion in 2023 and is expected to maintain a steady growth rate of 6% over the next three years, reaching $223 billion by 2026 [2] - The company operates as both a nutritional ingredient supplier and a formulation manufacturer, with strong competitiveness in HMB, glucosamine, and other nutritional ingredients [2] Product Segmentation - **HMB**: The company holds over 50% of the global market share and is a key player in the HMB industry, collaborating with major companies like Metabolic and Abbott to drive HMB commercialization [2] - **Glucosamine**: The company is a leading provider of high-quality glucosamine, achieving a stable global market share of 12.61% in 2024 [3] - **Other Nutritional Ingredients**: The company has enhanced its research capabilities through the strategic acquisition of Metabolic Technologies, focusing on new ingredient development [3] - **Formulation Business**: The company emphasizes innovative dosage forms and has obtained TGA GMP certification for its production facility, enabling it to offer personalized nutritional solutions [4] Financial Projections - The company is expected to achieve revenues of 1.184 billion yuan, 1.436 billion yuan, and 1.758 billion yuan from 2025 to 2027, with year-on-year growth rates of 18.2%, 21.2%, and 22.5% respectively [5] - Projected net profits for the same period are 199 million yuan, 239 million yuan, and 310 million yuan, with growth rates of 13.8%, 20.1%, and 30.1% respectively [5]

Core Viewpoint - Jiangyin Jiyuan Group Co., Ltd. successfully listed on the A-share market, marking a significant milestone for the company and the Jiangsu IPO landscape [3][8]. Company Overview - Jiyuan Group, founded in September 2002 by Zhou Jingshi, specializes in the research and production of dietary nutritional supplements [5]. - The company is led by General Manager Long Ling, who has played a key role in the commercialization of 22 patented products [5]. Product Portfolio - The main products include HMB raw materials, glucosamine series, chondroitin sulfate, and formulations, with projected revenues for 2024 being CNY 293 million, CNY 180 million, CNY 90 million, and CNY 350 million respectively [5]. - HMB raw materials hold a global market share of 53.34%, ranking first, largely due to the significant contribution from Abbott, which accounts for 73.35% of HMB revenue [5][6]. Market Position - The glucosamine series has a global market share of 12.61%, with clients including Blackmores and Royal Canin [6]. - Chondroitin sulfate targets the high-end pet nutrition market, with a global market share of 0.96% [6]. Financial Performance - Revenue figures from 2021 to 2024 are projected at CNY 801 million, CNY 947 million, CNY 892 million, and CNY 1 billion, with net profits of CNY 110 million, CNY 142 million, CNY 160 million, and CNY 174 million respectively [6]. IPO Details - The IPO application was accepted in March 2023, and the company successfully went public in July 2023, raising CNY 544 million with a net amount of CNY 480 million after expenses [8][9]. - The company issued 50.01 million shares at an initial price of CNY 10.88 per share, with a first-day closing price of CNY 40.75, reflecting a 274.54% increase and a market capitalization of CNY 16.3 billion [9]. Fund Utilization - The funds raised will be allocated to various projects, including CNY 206 million for a nutritional health raw material production base, CNY 147 million for expanding a production line, CNY 99.14 million for a technology innovation center, and CNY 150 million for working capital [8].

Group 1: Company Overview - Shanda Electric Power is an indirect holding company of Shandong University, primarily engaged in the research, manufacturing, sales, and service of smart grid monitoring and new energy-related products [1][5] - The company is recognized as a national-level specialized and innovative "little giant" enterprise and a gazelle enterprise in Shandong Province [1] - The main products include fault recording monitoring devices, transmission line fault monitoring devices, and time synchronization devices [1] Group 2: Financial Information - Shanda Electric Power's initial public offering (IPO) price was 14.66 CNY per share, with an institutional offering price of 15.06 CNY per share, resulting in a market capitalization of 2.388 billion CNY [2] - The company's earnings per share (EPS) is projected at a price-to-earnings (P/E) ratio of 19.57, compared to the industry average P/E ratio of 20.25 [2] - Revenue from the smart grid monitoring sector is expected to be 5.76 million CNY, accounting for 87.94% of total revenue, while the new energy sector is projected to contribute 0.79 million CNY, or 12.06% [6] Group 3: Fundraising and Investment Plans - Shanda Electric Power plans to allocate 1.35 billion CNY (27.00%) for smart grid fault analysis and intelligent distribution network equipment production projects [4] - The company intends to invest 1.80 billion CNY (36.00%) in a research and development center project [4] - Additional investments include 0.40 billion CNY (8.00%) for new energy vehicle smart charging pile production and 0.90 billion CNY (18.00%) for working capital [5] Group 4: Market Position and Client Relationships - Shanda Electric Power has established long-term stable partnerships with major clients such as State Grid and Southern Power Grid, enhancing its competitive edge in the smart grid monitoring and new energy sectors [5] - The company operates 17 liaison offices across major cities in China, covering 22 provinces, 5 autonomous regions, and 4 municipalities [5] Group 5: Risks and Challenges - The company has reported lower research and development (R&D) investment levels compared to industry peers, with R&D expenses of 31.43 million CNY, 37.58 million CNY, and 45.96 million CNY from 2022 to 2024, resulting in R&D expense ratios of 6.57%, 6.84%, and 6.98% respectively [6] - Shanda Electric Power is highly sensitive to revenue fluctuations from State Grid, with sensitivity coefficients of 1.53, 1.36, and 1.29 for the years 2022 to 2024 [6] Group 6: Company Overview (Jiyuan Group) - Jiyuan Group specializes in the research and industrialization of dietary nutritional supplements, providing nutritional raw materials and formulations [7] - The company has developed into a leading global supplier of HMB raw materials and high-quality glucosamine products [11] Group 7: Financial Information (Jiyuan Group) - Jiyuan Group's IPO price was 10.88 CNY per share, with an institutional offering price of 11.09 CNY per share, resulting in a market capitalization of 4.352 billion CNY [8] - The company has a projected P/E ratio of 25.51, with comparable companies showing higher dynamic P/E ratios [8] Group 8: Fundraising and Investment Plans (Jiyuan Group) - Jiyuan Group plans to invest 2.06 billion CNY (34.23%) in the construction of a nutritional health raw material production base [10] - Additional investments include 1.47 billion CNY (24.44%) for expanding the production line of nutritional health foods and 0.99 billion CNY (16.45%) for a technology innovation center [10] Group 9: Market Position and Client Relationships (Jiyuan Group) - The company has established partnerships with numerous global brands, including Abbott, Sanofi, and Nestlé, for the supply of HMB and other nutritional products [11] - Jiyuan Group's revenue from nutritional raw materials is projected to be 5.71 million CNY, 6.09 million CNY, and 6.47 million CNY from 2022 to 2024, maintaining a revenue contribution of over 60% [11]

Core Viewpoint - The company aims to enhance public health through the development and sale of dietary nutritional supplements, focusing on early detection and prevention of health risks, particularly through the use of nutrients like HMB [2][9]. Company Overview - The company, 技源集团, has over 20 years of experience in the dietary nutritional supplement industry and has established a global network for R&D, production, sales, and service, becoming the largest supplier of HMB raw materials worldwide [2][4]. - The company went public on July 23, with plans to use the IPO proceeds to expand production capacity and enhance R&D capabilities [2][8]. Product and Market Focus - HMB is identified as a crucial nutrient for maintaining muscle health, particularly beneficial for individuals over 35, aiding in muscle preservation and recovery [3][6]. - The company has developed a comprehensive product line that includes various forms of HMB and is collaborating with major firms like 蒙牛 to create specialized products [6][7]. Financial Performance - The company has shown strong financial growth, with projected revenues of 940 million, 890 million, and 1 billion yuan from 2022 to 2024, respectively, and net profits of 140 million, 160 million, and 170 million yuan [8]. - The global dietary supplement market is growing, with a consumption scale exceeding $150 billion in 2021, indicating a robust demand for nutritional products [8]. Strategic Development - The company has transitioned from a trading model to an integrated platform model, enhancing its capabilities across the entire supply chain from raw material production to finished product formulation [4][7]. - The company holds 147 domestic and international patents, including a patented HMB and Vitamin D3 combination that has shown superior effects in clinical trials [6][5]. Industry Context - As China faces an aging population, there is an increasing emphasis on health and wellness, positioning the company to contribute significantly to public health initiatives [9].

股票简称：技源集团 股票代码：603262 技源集团股份有限公司 TSI Group Co., Ltd. （江苏省江阴临港经济开发区锦绣路 2 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） （上海市中山南路 318 号东方国际金融广场 24 层） 二零二五年七月二十二日 1 特别提示 技源集团股份股份有限公司（以下简称"技源集团"、"发行人"、"公司" 或"本公司"）股票将于 2025 年 7 月 23 日在上海证券交易所主板上市。本公司 提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市初期 切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或者重大遗漏，并依 法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。 本 公 司 提 醒 广 大 投 资 者 认 真 阅 读 查 阅 刊 载 于 上 海 证 券 交 易 所 网站 （http://www.sse.com.c ...

Investment Rating - The report provides a positive investment rating for the health supplement industry, particularly highlighting the growth potential of the HMB segment and the overall market expansion [4][28]. Core Insights - The report emphasizes that the global dietary supplement industry is experiencing continuous expansion, with the market size expected to approach $200 billion by 2025, driven by increasing health awareness among consumers [28]. - The company, as the largest global supplier of HMB, is well-positioned to benefit from the growing demand for muscle health products, with a projected revenue increase of 22.8% in 2024 [49][60]. - The report also notes the company's strong partnerships with major clients like Abbott, which significantly contribute to its revenue, particularly in the HMB segment [55][111]. Financial Performance - The company achieved a revenue of 1.0 billion yuan in 2024, reflecting a year-on-year growth of 12.3% [3][7]. - The net profit attributable to shareholders reached 174.4 million yuan in 2024, with a compound annual growth rate (CAGR) of 16.7% from 2021 to 2024 [7][21]. - The gross margin improved to 43.5% in 2024, while the net margin slightly decreased to 17.5% due to a minor increase in expenses [21][22]. Revenue Breakdown - In 2024, the revenue from nutritional raw materials and formulations was 6.5 billion yuan and 3.5 billion yuan, respectively, accounting for 64.6% and 35.1% of total revenue [12][96]. - The HMB segment generated 2.93 billion yuan in revenue in 2024, representing 45.3% of the nutritional raw materials revenue [49][85]. - The company’s international sales are significant, with the U.S. accounting for 30.6% of revenue, indicating a strong presence in overseas markets [15]. Market Trends - The global sports nutrition market is projected to grow at a CAGR of 4.5% from 2020 to 2026, with HMB being a key ingredient driving this growth [33][35]. - The joint health supplement market, including glucosamine and chondroitin sulfate, is expected to maintain a steady growth rate of 5.8% from 2020 to 2027, supported by an aging population [39][41]. - The report highlights the increasing penetration of contract manufacturing in the health supplement industry, with a market size exceeding 100 billion yuan [45]. Production Capacity and Utilization - The company’s production capacity for HMB, glucosamine, and chondroitin sulfate is expected to exceed 90% utilization in 2024, indicating strong demand [117]. - The company plans to invest 210 million yuan to expand its production capacity for HMB and other nutritional raw materials, which will enhance its ability to meet growing market demands [117][120].

Group 1 - The core viewpoint of the news is that Jiyuan Group is launching an IPO to raise funds for expanding its production capacity and enhancing its R&D capabilities in the dietary supplement industry [1][2]. - Jiyuan Group plans to issue 50.01 million shares at a price of 10.88 yuan per share, with a total post-issue share capital of approximately 400 million shares [1]. - The company has established itself as a leading supplier in the global HMB market, holding over 50% market share and possessing multiple core patents and clinical data [2]. Group 2 - The company has shown steady growth in revenue and profit, with projected revenues of 9.47 billion yuan, 8.92 billion yuan, and 10.02 billion yuan from 2022 to 2024, and net profits of 1.42 billion yuan, 1.6 billion yuan, and 1.74 billion yuan respectively [2]. - The funds raised from the IPO, totaling 603 million yuan, will be allocated to the construction of a nutritional health raw material production base, expansion of production lines, and a technology innovation center [2]. - Jiyuan Group aims to continue its focus on technological innovation, increasing R&D investment, and optimizing production processes to enhance product quality and brand value [3].

Core Viewpoint - The company, Jiyuan Group, is launching an IPO with a share price of 10.88 yuan and a price-to-earnings ratio of 25.51, which is lower than the industry average of 27.69, indicating a potential investment opportunity in the dietary supplement sector [1]. Company Overview - Jiyuan Group specializes in the research, innovation, and industrialization of dietary nutritional supplements, providing original and customized nutritional raw materials and formulations globally [1]. - The company is a leading developer and market promoter of HMB nutrients, holding multiple core patents and extensive clinical data for its myHMB® brand [1]. Financial Performance - The projected revenues for Jiyuan Group are approximately 9.47 billion yuan in 2022, 8.92 billion yuan in 2023, and 10.02 billion yuan in 2024, with net profits of about 1.44 billion yuan, 1.61 billion yuan, and 1.75 billion yuan respectively [2]. - Total assets are expected to grow from 924.46 million yuan in 2022 to 1,186.02 million yuan in 2024, while equity attributable to shareholders is projected to increase from 599.85 million yuan to 937.21 million yuan over the same period [3]. - The company's debt-to-asset ratio is expected to decrease from 34.30% in 2022 to 20.23% in 2024, indicating improved financial stability [3]. Research and Development - Jiyuan Group invests approximately 4.96% of its revenue in research and development, reflecting its commitment to innovation in the dietary supplement industry [3].